Francesca Ghilascu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca Ghilascu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Botezatu
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
5 shared publications - Daniel Mocan
Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău
5 shared publications - Nicolae Bodrug
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
5 shared publications - Marcel Covalciuc
SC Liamed, Brașov
3 shared publications - Victoria Turcan
Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău
3 shared publications - Anastasia Comerzan2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by State Agency on Intellectual Property in Intellectus
- No. 1,p. 168-180
Hepatic Encephalopathy and Chronic Cerebrovascular Dysfunction (synthesis article)
Hepatic encephalopathy (HE) is a frequent and disabling complication of liver cirrhosis and chronic liver failure. While traditionally attributed primarily to hyperammonemia, growing evidence indicates that HE results from the interaction of metabolic disturbances, systemic inflammation, intestinal dysbiosis, and cerebrovascular dysfunction, supporting its reconceptualization as a chronic brain disorder. A narrative review of the international literature published between 2000 and 2025 was conducted using PubMed/Medline, Journal of Hepatology, SpringerLink, and Google Scholar. Human studies relevant to the pathophysiology, diagnosis, and management of hepatic encephalopathy - including randomized controlled trials, observational studies, meta-analyses, and international guidelines - were included and synthesized qualitatively. Contemporary evidence supports an integrative gut-liver-brain model in which hyperammonemia acts synergistically with systemic inflammation, microbiome alterations, and blood-brain barrier dysfunction. These mechanisms converge to induce neuroinflammation, astrocytic dysfunction, and impaired cerebral blood flow autoregulation. Clinically, HE manifests across a broad cognitive, behavioral, and neuromotor spectrum, including minimal and covert forms associated with significant functional impairment. Cerebrovascular dysfunction appears to contribute to persistent cognitive deficits even after metabolic correction. Hepatic encephalopathy should be conceptualized as a metabolic-inflammatory-vascular brain disorder. While established therapies targeting ammonia and precipitating factors remain fundamental, emerging adjunctive approaches aimed at modulating inflammation, microbiome composition, and cerebral microcirculation warrant further investigation within rigorously designed clinical trials.
- 1 June 2026
- Published by State Agency on Intellectual Property in Intellectus
- No. 1,p. 168-180
Open AccessHepatic Encephalopathy and Chronic Cerebrovascular Dysfunction (synthesis article)
Hepatic encephalopathy (HE) is a frequent and disabling complication of liver cirrhosis and chronic liver failure. While traditionally attributed primarily to hyperammonemia, growing evidence indicates that HE results from the interaction of metabolic disturbances, systemic inflammation, intestinal dysbiosis, and cerebrovascular dysfunction, supporting its reconceptualization as a chronic brain disorder. A narrative review of the international literature published between 2000 and 2025 was conducted using PubMed/Medline, Journal of Hepatology, SpringerLink, and Google Scholar. Human studies relevant to the pathophysiology, diagnosis, and management of hepatic encephalopathy - including randomized controlled trials, observational studies, meta-analyses, and international guidelines - were included and synthesized qualitatively. Contemporary evidence supports an integrative gut-liver-brain model in which hyperammonemia acts synergistically with systemic inflammation, microbiome alterations, and blood-brain barrier dysfunction. These mechanisms converge to induce neuroinflammation, astrocytic dysfunction, and impaired cerebral blood flow autoregulation. Clinically, HE manifests across a broad cognitive, behavioral, and neuromotor spectrum, including minimal and covert forms associated with significant functional impairment. Cerebrovascular dysfunction appears to contribute to persistent cognitive deficits even after metabolic correction. Hepatic encephalopathy should be conceptualized as a metabolic-inflammatory-vascular brain disorder. While established therapies targeting ammonia and precipitating factors remain fundamental, emerging adjunctive approaches aimed at modulating inflammation, microbiome composition, and cerebral microcirculation warrant further investigation within rigorously designed clinical trials.
- Open Access
- 1 June 2026
- Published by State Agency on Intellectual Property in Intellectus
- No. 1,p. 187-193
The Importance of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is recognized as a systemic disorder, involving airflow limitation, persistent inflammation, oxidative stress, and vascular dysfunction. Pulmonary hypertension (PH) is a clinically relevant and often underdiagnosed complication, impacting prognosis, functional capacity, and survival. Recent evidence shows that PH in COPD can develop early, even in moderate disease, and is associated with pulmonary vascular remodeling, endothelial dysfunction, and systemic inflammation. Distinct phenotypes, including disproportionate PH-COPD forms, exhibit severe hemodynamic impairment and poor outcomes. This review critically synthesizes current literature on the epidemiology, pathophysiology, clinical relevance, and therapeutic strategies for PH-COPD. Emerging complementary approaches targeting oxidative stress, inflammation, and endothelial dysfunction, including medical ozone therapy, are also discussed.
- 1 June 2026
- Published by State Agency on Intellectual Property in Intellectus
- No. 1,p. 187-193
Open AccessThe Importance of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is recognized as a systemic disorder, involving airflow limitation, persistent inflammation, oxidative stress, and vascular dysfunction. Pulmonary hypertension (PH) is a clinically relevant and often underdiagnosed complication, impacting prognosis, functional capacity, and survival. Recent evidence shows that PH in COPD can develop early, even in moderate disease, and is associated with pulmonary vascular remodeling, endothelial dysfunction, and systemic inflammation. Distinct phenotypes, including disproportionate PH-COPD forms, exhibit severe hemodynamic impairment and poor outcomes. This review critically synthesizes current literature on the epidemiology, pathophysiology, clinical relevance, and therapeutic strategies for PH-COPD. Emerging complementary approaches targeting oxidative stress, inflammation, and endothelial dysfunction, including medical ozone therapy, are also discussed.
- Open Access
- 23 January 2026
- Published by Periodic Publication Journal of Science, Innovation, Culture and Art "SCIENCE and INNOVATION" in Akademos
- No. 4(79),p. 59-68
Autohemoterapia hiperbară cu ozon în esofagul Barrett asociat infecției cu Helicobacter pylori: studiu clinic comparativ, controlat, longitudinal
Barrett’s Esophagus (BE) is a precancerous esophageal condition often associated with chronic gastroesophageal reflux, while the role of Helicobacter pylori (H. pylori) infection in its progression remains controversial. Oxidative stress and chronic inflammation are key factors in the advancement of esophageal metaplasia. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) emerges as a promising adjuvant therapeutic option due to its antioxidant and immunomodulatory effects. This study included 60 patients with BE and active H. pylori infection, randomized into two equal groups: one treated with standard therapy combined with AHT-O₃, and one receiving standard therapy alone. Over a 12-month period, clinical, endoscopic, histological, and paraclinical evaluations were performed, including markers of oxidative stress, immunophenotyping, H. pylori infection status, CRP levels, GIQLI scores, and the dynamics of esophageal lesions. Ozone therapy led to a significant reduction in the oxidative stress marker malondialdehyde (MDA) and a notable increase in antioxidant enzymes (SOD, GPx, GST), indicating a restoration of redox balance. Concurrently, a significant increase in T-helper cells and a decrease in inflammatory T cells were observed, reflecting a favorable immune response. Parameters specific to H. pylori infection (IgA, IgG, fecal antigen) showed a more pronounced reduction in the ozone treatment group, indicating superior eradication efficiency. CRP levels decreased significantly, and GIQLI scores revealed a marked improvement in the quality of life. Endoscopic and histological assessments demonstrated a significantly higher rate of complete or partial regression of Barrett’s lesions in the ozone-treated group. Hyperbaric ozone autohemotherapy, when integrated into the standard therapeutic regimen, proved effective in counteracting oxidative stress, modulating immune responses, and significantly improving the clinical and histological status of patients with BE and H. pylori infection. These results support the use of this method as a complementary therapeutic strategy with added value in gastroenterology.
- 23 January 2026
- Published by Periodic Publication Journal of Science, Innovation, Culture and Art "SCIENCE and INNOVATION" in Akademos
- No. 4(79),p. 59-68
Open AccessAutohemoterapia hiperbară cu ozon în esofagul Barrett asociat infecției cu Helicobacter pylori: studiu clinic comparativ, controlat, longitudinal
Barrett’s Esophagus (BE) is a precancerous esophageal condition often associated with chronic gastroesophageal reflux, while the role of Helicobacter pylori (H. pylori) infection in its progression remains controversial. Oxidative stress and chronic inflammation are key factors in the advancement of esophageal metaplasia. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) emerges as a promising adjuvant therapeutic option due to its antioxidant and immunomodulatory effects. This study included 60 patients with BE and active H. pylori infection, randomized into two equal groups: one treated with standard therapy combined with AHT-O₃, and one receiving standard therapy alone. Over a 12-month period, clinical, endoscopic, histological, and paraclinical evaluations were performed, including markers of oxidative stress, immunophenotyping, H. pylori infection status, CRP levels, GIQLI scores, and the dynamics of esophageal lesions. Ozone therapy led to a significant reduction in the oxidative stress marker malondialdehyde (MDA) and a notable increase in antioxidant enzymes (SOD, GPx, GST), indicating a restoration of redox balance. Concurrently, a significant increase in T-helper cells and a decrease in inflammatory T cells were observed, reflecting a favorable immune response. Parameters specific to H. pylori infection (IgA, IgG, fecal antigen) showed a more pronounced reduction in the ozone treatment group, indicating superior eradication efficiency. CRP levels decreased significantly, and GIQLI scores revealed a marked improvement in the quality of life. Endoscopic and histological assessments demonstrated a significantly higher rate of complete or partial regression of Barrett’s lesions in the ozone-treated group. Hyperbaric ozone autohemotherapy, when integrated into the standard therapeutic regimen, proved effective in counteracting oxidative stress, modulating immune responses, and significantly improving the clinical and histological status of patients with BE and H. pylori infection. These results support the use of this method as a complementary therapeutic strategy with added value in gastroenterology.
- 1 December 2025
- Published by State Agency on Intellectual Property in Intellectus
- No. 2,p. 212-225
Therapeutic and Immunological Effects of Systemic Ozone Therapy in Atrophic Gastritis with Active Helicobacter pylori Infection
Atrophic gastritis is a precancerous lesion frequently associated with active Helicobacter pylori infection, representing a major risk factor for gastric cancer. The present controlled and longitudinal study evaluated the efficacy of ozone hyperbaric autohemotherapy (AHT-O₃) as an adjuvant treatment. The group of 60 patients was divided into two equal groups: standard treatment and standard treatment + AHT-O₃. At 12 months, the H. pylori eradication rate was 96% in the AHT-O₃ group, compared to 73% in the control group. Also, ozone-treated patients showed a decrease in malondialdehyde (from 4.5 to 2.2 nmol/ml) and an increase in SOD (from 150 to 210 U/ml). Immunologically, the proportion of T helper lymphocytes increased by 14%, and mucosal inflammation was reduced. Endoscopically, 47% of ozone-treated patients showed normalization of the gastric mucosa. The therapy was well tolerated, without adverse reactions. The results support the integration of ozone therapy into the complex management of HP-positive atrophic gastritis, especially in cases resistant to standard treatment.
- 1 December 2025
- Published by State Agency on Intellectual Property in Intellectus
- No. 2,p. 212-225
Therapeutic and Immunological Effects of Systemic Ozone Therapy in Atrophic Gastritis with Active Helicobacter pylori Infection
Atrophic gastritis is a precancerous lesion frequently associated with active Helicobacter pylori infection, representing a major risk factor for gastric cancer. The present controlled and longitudinal study evaluated the efficacy of ozone hyperbaric autohemotherapy (AHT-O₃) as an adjuvant treatment. The group of 60 patients was divided into two equal groups: standard treatment and standard treatment + AHT-O₃. At 12 months, the H. pylori eradication rate was 96% in the AHT-O₃ group, compared to 73% in the control group. Also, ozone-treated patients showed a decrease in malondialdehyde (from 4.5 to 2.2 nmol/ml) and an increase in SOD (from 150 to 210 U/ml). Immunologically, the proportion of T helper lymphocytes increased by 14%, and mucosal inflammation was reduced. Endoscopically, 47% of ozone-treated patients showed normalization of the gastric mucosa. The therapy was well tolerated, without adverse reactions. The results support the integration of ozone therapy into the complex management of HP-positive atrophic gastritis, especially in cases resistant to standard treatment.
- 1 December 2025
- Published by State Agency on Intellectual Property in Intellectus
- No. 2,p. 191-205
Helicobacter pylori Infection - Associated Intestinal Metaplasia: A Comparative, Controlled, Longitudinal Clinical Study on the Efficacy of Hyperbaric Ozone Autohemotherapy
Gastric intestinal metaplasia is a precancerous lesion frequently associated with chronic H.pylori infection, representing a key stage in the gastric carcinogenesis cascade. Although bacterial eradication reduces the risk of progression to gastric adenocarcinoma, the efficacy of standard treatment in reversing intestinal metaplasia remains limited, particularly in extensive or incomplete forms. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) is proposed as a therapeutic adjuvant with antioxidant, anti-inflammatory and immunomodulatory potential. This comparative, controlled and longitudinal clinical study evaluated the efficacy of AHT-O₃ combined with conventional therapy in 60 adult patients diagnosed with intestinal metaplasia and active H.pylori infection. The AHT-O₃-treated group showed a significant reduction in malondialdehyde (MDA) levels and an increase in the activity of antioxidant enzymes (SOD, GPx, GST), compared to the control group (p less than 0.001). Additionally, a stimulation of T-helper lymphocytes and a decrease in pro-inflammatory lymphocytes were observed, indicating a robust immunoregulatory effect. The H.pylori eradication rate was higher in the ozone group (84% vs. 60%, p = 0.04), with a significantly greater decrease in IgA and IgG titers (p less than 0.01). Endoscopic and histological evaluation after 12 months showed an increased rate of complete and partial regression of intestinal metaplasia lesions and a marked reduction in gastric mucosal inflammation. The GIQLI score indicated a significant improvement in quality of life in the ozone-treated group. These results support the inclusion of AHT-O₃ as a viable complementary option in the therapeutic strategy for H.pylori-associated intestinal metaplasia, with a positive impact on the clinical, biochemical, and histological progression of the condition.
- 1 December 2025
- Published by State Agency on Intellectual Property in Intellectus
- No. 2,p. 191-205
Helicobacter pylori Infection - Associated Intestinal Metaplasia: A Comparative, Controlled, Longitudinal Clinical Study on the Efficacy of Hyperbaric Ozone Autohemotherapy
Gastric intestinal metaplasia is a precancerous lesion frequently associated with chronic H.pylori infection, representing a key stage in the gastric carcinogenesis cascade. Although bacterial eradication reduces the risk of progression to gastric adenocarcinoma, the efficacy of standard treatment in reversing intestinal metaplasia remains limited, particularly in extensive or incomplete forms. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) is proposed as a therapeutic adjuvant with antioxidant, anti-inflammatory and immunomodulatory potential. This comparative, controlled and longitudinal clinical study evaluated the efficacy of AHT-O₃ combined with conventional therapy in 60 adult patients diagnosed with intestinal metaplasia and active H.pylori infection. The AHT-O₃-treated group showed a significant reduction in malondialdehyde (MDA) levels and an increase in the activity of antioxidant enzymes (SOD, GPx, GST), compared to the control group (p less than 0.001). Additionally, a stimulation of T-helper lymphocytes and a decrease in pro-inflammatory lymphocytes were observed, indicating a robust immunoregulatory effect. The H.pylori eradication rate was higher in the ozone group (84% vs. 60%, p = 0.04), with a significantly greater decrease in IgA and IgG titers (p less than 0.01). Endoscopic and histological evaluation after 12 months showed an increased rate of complete and partial regression of intestinal metaplasia lesions and a marked reduction in gastric mucosal inflammation. The GIQLI score indicated a significant improvement in quality of life in the ozone-treated group. These results support the inclusion of AHT-O₃ as a viable complementary option in the therapeutic strategy for H.pylori-associated intestinal metaplasia, with a positive impact on the clinical, biochemical, and histological progression of the condition.